Literature DB >> 22547082

PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Ellen M McDonagh1, Catherine Wassenaar, Sean P David, Rachel F Tyndale, Russ B Altman, Michelle Whirl-Carrillo, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547082      PMCID： PMC3413746          DOI： 10.1097/FPC.0b013e3283540217

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  166 in total

1.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

Authors:  Kerri A Schoedel; Ewa B Hoffmann; Yushu Rao; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenetics       Date:  2004-09

2.  Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.

Authors:  Tatsuki Fukami; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; Haruko Sakai; Howard L McLeod; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2005-05-17       Impact factor: 3.922

3.  Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes.

Authors:  Federica Gemignani; Stefano Landi; Neonilia Szeszenia-Dabrowska; David Zaridze; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Lenka Foretova; Vladimir Janout; Vladimir Bencko; Valérie Gaborieau; Lydie Gioia-Patricola; Ilaria Bellini; Roberto Barale; Federico Canzian; Janet Hall; Paolo Boffetta; Rayjean J Hung; Paul Brennan
Journal:  Carcinogenesis       Date:  2007-01-27       Impact factor: 4.944

4.  Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

Authors:  K Ikeda; K Yoshisue; E Matsushima; S Nagayama; K Kobayashi; C A Tyson; K Chiba; Y Kawaguchi
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

5.  Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity.

Authors:  J S Miles; W Bickmore; J D Brook; A W McLaren; R Meehan; C R Wolf
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

6.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

7.  Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.

Authors:  Huijuan Wang; Ting Bian; Duan Liu; Tianbo Jin; Yong Chen; Aifen Lin; Chao Chen
Journal:  Pharmacogenomics       Date:  2011-04       Impact factor: 2.533

8.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

9.  Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.

Authors:  J S Miles; A W McLaren; L M Forrester; M J Glancey; M A Lang; C R Wolf
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

10.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.

Authors:  Jason K Yano; Mei-Hui Hsu; Keith J Griffin; C David Stout; Eric F Johnson
Journal:  Nat Struct Mol Biol       Date:  2005-08-07       Impact factor: 15.369
View more
  24 in total

1.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

2.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

3.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking.

Authors:  Neal L Benowitz; Gideon St Helen; Natalie Nardone; Lisa Sanderson Cox; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

Review 5.  Biochemical Verification of Tobacco Use and Abstinence: 2019 Update.

Authors:  Neal L Benowitz; John T Bernert; Jonathan Foulds; Stephen S Hecht; Peyton Jacob; Martin J Jarvis; Anne Joseph; Cheryl Oncken; Megan E Piper
Journal:  Nicotine Tob Res       Date:  2020-06-12       Impact factor: 4.244

6.  Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.

Authors:  Li-Shiun Chen; Sarah M Hartz; Timothy B Baker; Yinjiao Ma; Nancy L Saccone; Laura J Bierut
Journal:  Pharmacogenomics       Date:  2018-11-16       Impact factor: 2.533

7.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

8.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

9.  Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.

Authors:  Neal L Benowitz; Gideon St Helen; Delia A Dempsey; Peyton Jacob; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2016-07       Impact factor: 2.089

10.  Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).

Authors:  Li-Shiun Chen; A Joseph Bloom; Timothy B Baker; Stevens S Smith; Megan E Piper; Maribel Martinez; Nancy Saccone; Dorothy Hatsukami; Alison Goate; Laura Bierut
Journal:  Addiction       Date:  2013-11-11       Impact factor: 6.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.